Semaglutide (Wegovy) vs. Empagliflozin (Jardiance): A Patient Guide
Semaglutide (Wegovy) and Empagliflozin (Jardiance) are both prescription medications that can help with various health conditions, including cardiovascular benefits. While Wegovy is primarily known for weight loss, Jardiance is widely used for heart failure, kidney disease, and type 2 diabetes. This guide will help you understand their key differences.
Side-by-Side Comparison
| Category | Semaglutide | Empagliflozin |
|---|---|---|
| Drug Class | GLP-1 Receptor Agonist | SGLT2 Inhibitor |
| Primary Use | Weight loss (adults and children 12+), cardiovascular risk reduction in adults with established cardiovascular disease. | Heart failure, chronic kidney disease, type 2 diabetes (to reduce cardiovascular death/hospitalization). |
| Mechanism of Action | Mimics a natural hormone (GLP-1) to regulate appetite, slow stomach emptying, and improve blood sugar control. | Blocks glucose reabsorption in the kidneys, causing excess glucose to be removed through urine. |
| Key Advantage | Significant weight loss, also reduces major adverse cardiovascular events. | Proven benefits for heart failure, chronic kidney disease, and cardiovascular death reduction. |
| Main Limitation | Requires injections, potential for gastrointestinal side effects like nausea and vomiting, risk of pancreatitis and gallbladder issues. | Risk of genitourinary infections, dehydration, and diabetic ketoacidosis (especially in type 1 diabetes). |
| Administration | Once-weekly subcutaneous injection. | Once-daily oral tablet. |
| When to Choose | A doctor might choose Semaglutide (Wegovy) if the primary goal is significant weight loss in adults or adolescents, especially if there's also a need to reduce cardiovascular risks. It's also considered when other weight management strategies haven't been successful. | Empagliflozin (Jardiance) would be a preferred choice for patients with heart failure or chronic kidney disease, regardless of their diabetes status, due to its proven benefits in these conditions. It's also a strong option for adults with type 2 diabetes who need to reduce their risk of cardiovascular death or hospitalization. |
| Side Effects | Semaglutide commonly causes gastrointestinal side effects like nausea, vomiting, diarrhea, or constipation, and carries warnings for pancreatitis and gallbladder issues. Empagliflozin's common side effects include urinary tract infections, yeast infections, and increased urination, with warnings for dehydration and diabetic ketoacidosis. | |
| Cost | Both Semaglutide (Wegovy) and Empagliflozin (Jardiance) are brand-name medications without generic versions currently available, meaning they can be quite expensive. Insurance coverage varies widely and can significantly impact out-of-pocket costs. |
Bottom Line
Semaglutide (Wegovy) is primarily a weight-loss medication with cardiovascular benefits, administered by injection. Empagliflozin (Jardiance) is an oral medication with strong benefits for heart failure, kidney disease, and type 2 diabetes. Your doctor will consider your specific health conditions, treatment goals, and potential side effects to determine which medication is best suited for you.
Semaglutide Overview
Semaglutide is a once-weekly (or once-daily oral) GLP-1 receptor agonist that lowers blood sugar and reduces body weight by mimicking the natural gut hormone GLP-1. It is sold under three brand names — Ozempic (injectable, type 2 diabetes), Wegovy (injectable, weight management), and Rybelsus (oral tablet, type 2 diabetes) — all manufactured by Novo Nordisk. Clinical trials show it reduces HbA1c by up to 2.0 percentage points and body weight by up to 15% at the highest injectable dose.
Full Semaglutide guide →Empagliflozin Overview
Empagliflozin (Jardiance) is a medication that helps your kidneys remove extra sugar from your body through urine. It is prescribed to treat type 2 diabetes by lowering blood sugar, and also helps reduce the risk of heart-related problems and hospitalizations in adults with heart failure or chronic kidney disease.
Full Empagliflozin guide →Compare prices for Semaglutide and Empagliflozin
Check real-time pharmacy prices before you fill — free, no account needed.
Protect your muscle mass on GLP-1 medications
GLP-1 medications can cause up to 39% muscle loss alongside fat. Zova's AI-powered protocol — backed by Lancet Diabetes & Endocrinology research — reduces that to just 8.7% through leucine tracking and injection-day adaptive nutrition.
No credit card. No commitment.
Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.